Related Business Topics
Latest Headlines
Reuters - Nov. 25, 2009, 2:34 PM
NEWARK, Del.--(Business Wire)-- PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development ...
Forbes.com - Nov. 25, 2009, 1:40 PM
BusinessWire - PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation. These companies have interesting business models and they have to execute on the business development level to bring ...
CNBC - Nov. 25, 2009, 1:32 PM
Forbes.com - Nov. 25, 2009, 12:16 PM
1426 ET 25Nov2009 Option gauges suggest positive stock outlook ------------------------------------------------------------------------------ A number of option gauges are signaling a positive outlook for U.S. stocks among investors. An especially ...
Forbes.com - Nov. 25, 2009, 9:28 AM
1140 ET 25Nov2009-Big day for gold miners as gold breaks record ------------------------------------------------------------------------------ Shares in U.S. listed gold miners were having a big day on Wednesday as gold broke yet another record, boosted ...
Reuters - Nov. 25, 2009, 9:19 AM
* Novartis to pay Incyte $150 million upfront * Also pays $60 mln milestone at start of Phase III trial * Incyte shares rise 5.3 pct; Novartis up 0.6 pct (Adds Incyte share activity, further analyst comment) ZURICH, Nov 25 (Reuters) - Swiss drugmaker ...
Reuters - Nov. 25, 2009, 8:30 AM
strikes licensing deal with Incyte Reuters adsrc 'reuters.co.uk/finance/deals/regulatory/article;' ( typeof(AD_TRACKER) 'undefined' AD_TRACKER.globalAdSrcType null ) ((typeof (hideAllAds) 'undefined' hideAllAds false) (typeof (AD_TRACKER) 'undefined' ...
Forbes.com - Nov. 25, 2009, 7:59 AM
ZURICH, Nov 25 (Reuters) - Swiss drugmaker Novartis has struck a licensing deal with Incyte Corp , paying $150 million up front for access to therapies to treat patients with life-threatening blood disorders and cancers. Incyte shares rose as much as ...
Forbes.com - Nov. 25, 2009, 7:58 AM
Reuters Messaging rm://ellis.mnyandu.reuters.com@reuters.net 0911 EST 25Nov2009-Incyte shares rise after Novartis deal ------------------------------------------------------------------------------ Incyte Corp shares jumped 8.8 percent to $8.40 in ...
Forbes.com - Nov. 25, 2009, 6:58 AM
0911 EST 25Nov2009-Incyte shares rise after Novartis deal ------------------------------------------------------------------------------ Incyte Corp shares jumped 8.8 percent to $8.40 in premarket trading on Wednesday after Swiss drugmaker Novartis ...
0-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
I
Incyte Pharmaceuticals
Incyte's platform includes database products, genomic data management software tools, microarrays, and related reagents and services which Incyte provides to the pharmaceutical and biotechnology industries to assist their drug discovery and deve...
www.incyte.com
Incyte's platform includes database products, genomic data management software tools, microarrays, and related reagents and services which Incyte provides to the pharmaceutical and biotechnology industries to assist their drug discovery and deve...
www.incyte.com
